TuHURA

We are a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy.

[TuHURA @TuhuraBio]

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

https://t.co/HMpFxH6qQg
$HURA #BispecificADCs #BispecificPDCs #MerkelCell

[TuHURA @TuhuraBio]

We are leveraging our technology platform to develop next-generation candidates and expand into blood-related cancers.

$HURA #BispecificADCs #BispecificPDCs #MerkelCell

[TuHURA @TuhuraBio]

Be the first to know when we post new updates. Stay informed by signing up here:
https://t.co/tZl8UFfprc

$HURA #BispecificADCs #BispecificPDCs #MerkelCell

[TuHURA @TuhuraBio]

Dr. Tendler believes TuHURA's innovative portfolio has the potential to impact immuno-oncology and is excited to contribute his oncology drug development expertise to the Board and management for the company's growth and success.

https://t.co/sBeqkS9lDA
$HURA #MerkelCell

[TuHURA @TuhuraBio]

We’ll be at the 37th Annual Roth Conference, March 16th-18th, 2025, in Dana Point, CA! Looking forward to connecting with everyone there!

https://t.co/URY76fJuLB

$HURA #BispecificADCs #BispecificPDCs #MerkelCell

[TuHURA @TuhuraBio]

James Bianco, CEO of TuHURA, shares his excitement in welcoming Dr. Craig Tendler to the Board of Directors. He highlights Dr. Tendler's expertise in oncology development to support TuHURA’s Phase 3 trial and cancer immunotherapy pipeline.

https://t.co/sBeqkS9lDA
$HURA

[TuHURA @TuhuraBio]

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors

https://t.co/sBeqkS9lDA
$HURA

[TuHURA @TuhuraBio]

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

$HURA #BispecificADCs #BispecificPDCs #MerkelCell
https://t.co/URY76fJuLB

[TuHURA @TuhuraBio]

While checkpoint inhibitors have revolutionized cancer treatment, overcoming tumor resistance is still a key challenge to improving patient outcomes. Learn how we are working to address this issue: https://t.co/rshry0yx6s

$HURA #BispecificADCs #BispecificPDCs #MerkelCell

[TuHURA @TuhuraBio]

#InCaseYouMissedIt: $HURA participated in the #VirtualInvestor "Top 5 for '25" conference.

Watch it here: https://t.co/BKrfF8MUnY

@investorvirtual #BispecificADCs #BispecificPDCs #MerkelCell

[TuHURA @TuhuraBio]

Although #NationalCancerPreventionMonth is ending, the fight to #preventcancer continues. Support research by joining the American Association for Cancer Research in making a difference. Learn more here: https://t.co/0W6kUgsn8a

$HURA #BispecificADCs #BispecificPDCs #MerkelCell

[TuHURA @TuhuraBio]

Sign Up for Alerts! Get notified first when we
post new information.

https://t.co/tZl8UFeRBE
$HURA #BispecificADCs #BispecificPDCs #MerkelCell

[TuHURA @TuhuraBio]

#CheckOut Our Innovative Immuno-Oncology Pipeline!

https://t.co/sHvqpnMFRn
$HURA #BispecificADCs #BispecificPDCs #MerkelCell

[Virtual Investor Co. @InvestorVirtual]

What’s Next for 2025? 🚀 @TuhuraBio participated in the #VirtualInvestor Top 5 for '25 conference. Watch it here: https://t.co/RVmsq74ex2

$HURA #BispecificADCs #BispecificPDCs #MerkelCell

[Virtual Investor Co. @InvestorVirtual]

Virtual Investor "Top 5 for '25" Conference Now Available On-Demand.
@AkariTX @AutonomixMed @Amerresources @cns_pharma @enVVenoMedical @ExxelPharm @GRI_BIO @KaidaBio @OutlookTx @PalisadeBio @TuhuraBio

https://t.co/ysHE8ca6cF
$AKTX $AMIX $AREC $CNSP $NVNO $GRI $OTLK $PALI $HURA

[TuHURA @TuhuraBio]

TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference

https://t.co/poMXjSqi6s
$HURA #BispecificADCs #BispecificPDCs #MerkelCell

[TuHURA @TuhuraBio]

#DidYouKnow: The incidence of Merkel Cell Carcinoma in the US is approximately 2,500 cases per year, and it's expected to increase by 30% by 2025. At TuHURA, we are committed to making a difference.

Learn more about our efforts: https://t.co/qBjpH3EaXV
$HURA #MerkelCell

[TuHURA @TuhuraBio]

We are developing two innovative platform technologies to overcome two major obstacles limiting the effectiveness of cancer immunotherapies for multiple cancers with significant unmet needs.

$HURA #BispecificADCs #BispecificPDCs #MerkelCell

[TuHURA @TuhuraBio]

This February, in honor of #NationalCancerPreventionMonth, take the opportunity to learn how to protect your health and reduce cancer risks. Explore helpful tips and resources here: https://t.co/0W6kUgsn8a

$HURA #BispecificADCs #BispecificPDCs #MerkelCell

[TuHURA @TuhuraBio]

Take action this #WorldCancerDay and discover how you can contribute to the fight against cancer. Find out more and get involved here: https://t.co/9xI3Zle8ny

$HURA #BispecificADCs #BispecificPDCs #MerkelCell